ArticleScientific reports2026
Integrated bioinformatics analysis reveals fatty acid metabolism subtypes and immune landscape in recurrent implantation failure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microarray and RNA-sequencing datasets for recurrent implantation failure (RIF) were retrieved from the Gene Expression Omnibus (GEO) database. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were subsequently integrated with lipid metabolism-related gene sets to identify candidate biomarkers. Cross-analysis of these approaches yielded seven candidate genes, which were then subjected to four machine learning algorithms. This led to the identification of five hub genes: PRKAG2, CPT1A, PPARGC1A, PIK3C2G, and PTGS2. Logistic regression further validated these genes as robust biomarkers, enabling the construction of a diagnostic nomogram. Molecular docking using CB-Dock Tools subsequently demonstrated that peucedanin binds favorably to all five hub gene products. Collectively, these findings highlight PRKAG2, CPT1A, PPARGC1A, PIK3C2G, and PTGS2 as promising diagnostic biomarkers for RIF and offer new perspectives for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.